How Photoacoustic Imaging Works — and Why It Matters Now

Photoacoustic imaging (PAI) — also termed optoacoustic imaging — is a hybrid biomedical modality that combines pulsed optical excitation with ultrasound detection to deliver high-contrast, high-resolution images of tissue structure and function at clinically relevant depths. The underlying mechanism is the photoacoustic effect: absorbed pulsed light causes thermoelastic expansion that generates broadband acoustic waves, which are then detected by conventional ultrasound transducers. Because sound scatters far less than light in biological tissue, PAI achieves optical contrast at ultrasonic imaging depths — overcoming the fundamental limitation of purely optical techniques such as fluorescence microscopy.

The photoacoustic effect was first characterised by Alexander Graham Bell in the 1880s, yet its application to biomedical imaging has only matured over the past two decades. Three primary imaging architectures now dominate the literature. Photoacoustic Computed Tomography (PACT) uses array-based detection with computational reconstruction, suited for deep-tissue and whole-organ imaging. Photoacoustic Microscopy (PAM) employs point-scanning in either optical-resolution (OR-PAM) or acoustic-resolution (AR-PAM) modes, optimised for high-resolution superficial imaging. Photoacoustic Endoscopy/Endomicroscopy (PAE/PAEM) uses miniaturised fiber-optic probes to deliver light internally for access to deep organs.

The dual PAT/US platform — integrating photoacoustic tomography with conventional B-mode ultrasound — has emerged as the most clinically tractable configuration, leveraging established ultrasound infrastructure and clinical familiarity. According to research published by WIPO-tracked institutions and reviewed by PatSnap, this hybrid approach substantially reduces adoption barriers compared to standalone PAI systems.

17 Years of Innovation: From Proof-of-Concept to Clinical Translation

The photoacoustic imaging innovation timeline spans approximately 17 years of documented progress, from early system demonstrations in 2007 through to regulatory-oriented designs filed in 2024. This trajectory divides into three distinct phases, each characterised by a shift in the dominant research and commercialisation challenge.

Foundational Phase (2007–2013)

Early system demonstrations using interferometric detection and CCD-based optical ultrasound established proof-of-concept imaging. The University of California, Irvine demonstrated sub-200 µm resolution in phantoms as early as 2007. Karl-Franzens-University Graz subsequently achieved sub-100 µm 3D resolution using CCD-camera-based ultrasound detection. A landmark translational milestone arrived in 2013 when the Helmholtz Center Munich reported a functional optoacoustic handheld video-rate 3D scanner tested in human volunteers — the first demonstration of real-time volumetric PAI in a clinical-adjacent setting.

Development and Scale-Up Phase (2015–2019)

Systems expanded to breast-specific tomography, MEMS-enhanced microscopy, LED-based sources, and clinical-grade handheld probes. FUJIFILM Corporation filed multiple active US design patents for probe designs between 2016 and 2017, signalling a move toward commercialisation. POSTECH introduced a programmable real-time clinical photoacoustic and ultrasound imaging system in 2016 — one of the first systems designed explicitly for clinical workflow integration.

Clinical Translation Phase (2020–2024)

The most recent phase is characterised by cost reduction, LED-based sources, dual-modal PAT/US platforms, and regulatory-ready designs. FUJIFILM’s EP-active patent filed in 2024 focuses specifically on monitoring blood vessel regeneration treatment — a direct clinical use-case indicator. Literature volume on LED sources and portable systems accelerated markedly post-2019, signalling intensifying commercialisation pressure across the sector.

“The Helmholtz Center Munich reported a functional optoacoustic handheld video-rate 3D scanner in human volunteers as early as 2013 — a landmark translational result that preceded the current commercialisation wave by nearly a decade.”

Four Technology Clusters Driving the Field Forward

Photoacoustic imaging innovation organises into four distinct technical clusters, each addressing a different constraint — from depth and sensitivity to miniaturisation and cost — and each attracting a different mix of academic and commercial contributors.

Cluster 1: Laser-Based High-Power Pulsed Systems

The traditional architecture employs Q-switched Nd:YAG or OPO lasers delivering nanosecond pulses at high peak energies. These systems achieve the deepest penetration depths and highest signal-to-noise ratios but are bulky and expensive. NIR-I excitation (700–900 nm) is established as optimal for depth, while NIR-II windows (1000–1700 nm) are being explored for further gains. Research from Nanyang Technological University in 2019 directly compared imaging depth at 532 nm, 800 nm, and 1064 nm wavelengths, providing empirical validation of the NIR advantage.

Cluster 2: LED and Low-Cost Portable Light Sources

A major innovation thrust since approximately 2018 has been replacing expensive class-IV lasers with pulsed LED arrays. LED systems sacrifice peak power but gain portability, safety, and cost-effectiveness, enabling point-of-care and resource-limited settings. Signal averaging at high pulse repetition frequencies — up to 16 kHz — compensates for lower per-pulse energy. Research from the University of California San Diego (2018) and Penn State Hershey College of Medicine (2021) has directly characterised LED performance against laser benchmarks, while a Tongji University review (2020) mapped the clinical translation pathway for LED-based systems.

Cluster 3: Fiber-Optic, All-Optical, and Minimally Invasive Systems

To access deep-seated or internal anatomy, fiber-optic light delivery and all-optical ultrasound detection — using interferometric sensors and optical resonators rather than piezoelectric elements — have been developed. These architectures enable miniaturised endoscopic probes, wearable configurations, and electromagnetic-interference-free imaging environments. King’s College London and University College London have been leading contributors in this cluster, with a 2018 demonstration of an all-optical dual photoacoustic and OCT intravascular probe representing a particularly significant advance for coronary imaging. Standards bodies including IEEE have begun tracking all-optical sensor specifications relevant to this cluster.

Cluster 4: MEMS-Enhanced and High-Speed Scanning Systems

Microelectromechanical systems (MEMS) scanners have dramatically increased PAM imaging speed, enabling video-rate acquisition and handheld miniaturised devices with both OR-PAM and AR-PAM capability. POSTECH has been the dominant contributor in this cluster, publishing multiple high-impact papers between 2016 and 2019 on programmable clinical systems and high-speed multiscale microscopy. The California Institute of Technology’s PATER (photoacoustic topography through an ergodic relay) architecture, demonstrated in 2020, represents a novel variant enabling functional imaging and biometric applications.

Clinical and Industrial Application Domains

Photoacoustic imaging addresses a broad and expanding range of application domains, from oncology and ophthalmology to surgical guidance and non-destructive industrial inspection. The maturity of each application varies considerably, reflecting differences in regulatory pathway complexity, clinical need, and hardware readiness.

Oncology and Breast Cancer Screening

Breast imaging represents the most mature clinical application in the dataset. The high vascular contrast of PAI maps tumour angiogenesis without ionising radiation or contrast injection. Multiple dedicated breast tomography systems have been reported, including hemispherical detector array configurations developed at the University of Twente. This application benefits from a clear clinical need — improved specificity over mammography — and a relatively accessible regulatory pathway as a diagnostic adjunct.

Ophthalmology and Retinal Imaging

Photoacoustic ophthalmoscopy (PAOM) has demonstrated capability to image retinal vasculature, choroidal vessels, and retinal pigment epithelium, complementing OCT. The University of Michigan has been a leading contributor, publishing studies on intraocular tumour imaging (2017), PAOM principles (2018), and safety evaluation within ANSI limits (2022). Safety confirmation within established optical exposure limits is a prerequisite for clinical adoption, and the 2022 safety study represents a significant step toward regulatory submission.

Cardiovascular and Vascular Imaging

PAI enables label-free mapping of blood oxygenation (sO₂), vascular anatomy, and arterial plaque composition. Intravascular dual-modal probes combining PA and OCT have been demonstrated in coronary artery disease contexts by researchers at Royal Free Hospital and King’s College London. A 2022 review from the Fifth People’s Hospital of Chengdu summarised the current clinical status and future trends of dual-modal PAT/US imaging, reflecting growing clinical engagement in China.

Surgical Guidance and Interventional Imaging

PAI via fiber-optic probes enables intraoperative visualisation of blood vessels, nerves, and instrument tips hidden beneath tissue surfaces — targeting minimally invasive surgical workflows. Johns Hopkins University published a comprehensive review of surgical guidance applications in 2020, and Washington University in St. Louis demonstrated optical-resolution photoacoustic endomicroscopy in vivo as early as 2015. FUJIFILM holds an active EP patent for a photoacoustic image generation method and device (2018) directly applicable to this domain.

Inflammation, Dermatology, and Musculoskeletal Imaging

Superficial applications — including imaging inflammatory disease such as rheumatoid arthritis and psoriasis, skin lesions, and musculoskeletal structures — exploit the high spatial resolution of PAM. The University of Cambridge Cancer Research UK published on optoacoustic imaging in inflammation in 2021, and the University of Michigan extended its PAI programme to musculoskeletal and abdominal imaging in 2023.

Non-Destructive Testing and Industrial Inspection

Beyond biomedicine, PAI has been applied to imaging railway cracks, lithium-metal battery defects, silicon wafer damage, porosity characterisation, and heritage artworks. Shanghai Jiao Tong University published a comprehensive review of photoacoustic NDT applications in 2021. This vertical remains underexplored relative to its potential, particularly where non-contact, depth-resolved inspection is required — an area where PAI offers advantages over conventional ultrasonic testing methods tracked by ISO standards bodies.

IP Landscape: FUJIFILM’s Patent Concentration and Geographic Signals

FUJIFILM Corporation is the most prolific commercial patent assignee in the photoacoustic imaging dataset, holding 6 active utility and design patents filed in US and EP jurisdictions between 2016 and 2024 — a concentration that signals both commercial intent and potential freedom-to-operate constraints for new entrants.

The US patent portfolio focuses on probe hardware — fiber arrangement, transducer geometry, and ergodic relay architectures — filed as design patents between 2016 and 2017. The EP portfolio covers image generation methods (2018) and, most recently, quantitative image evaluation for therapeutic monitoring (2024). IP strategists entering the probe design space must navigate FUJIFILM’s portfolio carefully; freedom-to-operate analysis around probe configurations is essential before product development commitments are made.

Academic innovation is geographically distributed across North America, Europe, East Asia, and Singapore, with no single geography dominating. Key academic clusters include POSTECH (South Korea) for MEMS and clinical systems; University of Michigan (USA) for ophthalmology and musculoskeletal imaging; King’s College London and UCL (UK) for minimally invasive and all-optical systems; University of Twente (Netherlands) for breast tomography; and Helmholtz Center Munich and Technical University of Munich (Germany) for volumetric MSOT and image reconstruction. Patent filing activity, by contrast, is concentrated in Japan through FUJIFILM for hardware and probe design, while US and EP jurisdictions host the active filings.

According to EPO filing data and PatSnap analysis, the dual-modal PAT/US platform is emerging as the most clinically tractable near-term configuration, and product developers should consider targeting FDA 510(k) pathways by positioning PAT as an add-on module to already-cleared ultrasound platforms. This approach leverages established clinical familiarity and infrastructure while reducing the regulatory burden associated with entirely novel device categories.

Emerging Directions and Strategic Implications for 2026

The most recent records in the dataset (2022–2024) point to five emerging directions that will shape the photoacoustic imaging competitive landscape over the next three to five years, each with distinct R&D, IP, and commercial implications.

1. Blood Vessel Regeneration Monitoring

FUJIFILM’s EP-active patent filed in 2024 introduces quantitative tracking of blood vessel regeneration treatment over time using differential photoacoustic image analysis. This is a direct therapeutic monitoring application — moving PAI from diagnostic imaging into treatment response assessment — with significant regulatory and commercial implications for oncology and wound care markets.

2. Forward-Viewing Photoacoustic Endomicroscopy with Transparent Sensors

King’s College London published in 2022 on wavefront shaping-assisted forward-viewing photoacoustic endomicroscopy based on a transparent PVDF/ITO ultrasound sensor on a multimode fiber. This configuration enables optical-resolution forward-viewing endoscopy — essential for tumour biopsy guidance — and represents a meaningful advance over side-viewing probe architectures that dominate the current literature.

3. Theranostic Contrast Agents and “Turn-On” Probes

Two 2022 publications — from Xi’an Jiaotong University and the University of Queensland — represent a convergence of molecular imaging and therapy. Stimuli-responsive nanomaterials and organic dyes provide target-specific PA signal activation, enabling “turn-on” probes that generate signal only in the presence of specific disease biomarkers. This approach offers exquisite disease specificity but faces significant regulatory hurdles for in vivo human use, requiring partnerships between imaging hardware companies and pharmaceutical or nanomedicine developers.

4. Extended Depth-of-Focus Microscopy

Helmholtz Center Munich demonstrated in 2022 that coupling Bessel beam illumination with axicon acoustic detection extends volumetric imaging depth-of-field by 17-fold, addressing a fundamental limitation of OR-PAM for fast 3D imaging. This development has direct implications for whole-organ PAM workflows where maintaining resolution across depth has previously required mechanical refocusing.

“LED-based systems represent the highest-growth commercial opportunity near-term. The cost, safety, and miniaturisation advantages strongly favour point-of-care and lower-resource clinical settings.”

5. Image Quality Standardisation for Clinical Approval

A 2022 systematic review from Aristotle University of Thessaloniki on image quality improvement techniques and assessment adequacy in clinical optoacoustic imaging reflects growing regulatory and standardisation activity. Standardisation is a prerequisite for FDA and CE clearance, and the timeline for commercial PAI adoption will be substantially determined by when consensus image quality metrics are established and accepted by regulators. R&D teams should engage proactively with standardisation bodies — including those tracked by FDA — to influence metric definitions that favour their platform architectures.

Strategic Priorities for R&D and IP Teams

• LED-based systems: Prioritise SNR optimisation and regulatory validation for LED platforms, which represent the highest-growth commercial opportunity near-term.
• Probe IP: Conduct freedom-to-operate analysis around FUJIFILM’s probe configurations before committing to hardware designs in US and EP markets.
• Regulatory pathway: Target FDA 510(k) by positioning PAT as an add-on module to cleared ultrasound platforms, leveraging established clinical familiarity.
• Theranostics: Pursue partnerships between imaging hardware companies and pharmaceutical or nanomedicine developers to realise “turn-on” contrast agent potential.
• Industrial diversification: Evaluate PAI technology for battery, semiconductor, and infrastructure inspection markets, where non-contact depth-resolved inspection is needed and competition from established imaging modalities is limited.